TL;DR
This Phase 3 clinical trial demonstrates that CU-30101, a new topical anesthetic cream, is equivalent in efficacy and safety to Pliaglis, a well-established anesthetic, for use during facial fractional laser resurfacing in Chinese adults. This finding suggests CU-30101 is a viable alternative for pain management in aesthetic procedures, particularly in markets where Pliaglis is not readily available.
What Problem Does This Paper Address?
Fractional laser resurfacing is a popular cosmetic procedure for improving skin texture, reducing wrinkles, and treating acne scars. However, these treatments can be quite painful, necessitating effective topical anesthesia to improve patient comfort and compliance. While several topical anesthetics exist, the market in China has a notable lack of approved lidocaine and tetracaine cream products. Pliaglis, a cream containing 7% lidocaine and 7% tetracaine, is a known effective option, but it's not widely available in China. CU-30101 is a newly developed topical cream with the same active ingredients and concentrations as Pliaglis, and it shares the unique characteristic of forming a peel-off film after application, eliminating the need for additional occlusive dressings. This study aims to rigorously evaluate whether CU-30101 can provide equivalent pain relief and safety compared to Pliaglis in a Chinese population undergoing fractional laser resurfacing.
Methods
This was a multicenter, randomized, double-blind, active-controlled, paired-design Phase 3 clinical trial. Chinese adults scheduled for fractional laser facial procedures were enrolled across nine medical centers. Participants were randomized to receive either CU-30101 or Pliaglis on opposite sides of their face prior to laser application, with treatment sequences assigned to two groups (Sequence A and Sequence B). This paired design allowed for direct comparison within each individual.
The primary efficacy endpoint was pain assessment using the Visual Analog Scale (VAS), a 100-mm scale where 0 is "no pain" and 100 is "most pain imaginable." Participants reported their pain immediately after the fractional laser treatment on each side of their face. Secondary endpoints included participant and investigator satisfaction with the anesthesia, local tolerability, and overall safety.
Randomization was performed using SAS software with a block randomization approach. Blinding was maintained by using uniform external packaging for both products, while internal packaging differed slightly. Non-blinded personnel applied and removed the drugs, and participants were blindfolded during this process. Investigators were blinded to the treatment assigned to each side.
Statistical analysis focused on demonstrating equivalence. The primary efficacy analysis used a paired t-test on the VAS scores. Equivalence was established if the 95% confidence interval (CI) for the mean difference in VAS scores between the CU-30101 and Pliaglis sides fell within a predefined equivalence margin of ±4.7 VAS points. Supportive analyses were conducted on the per-protocol set. Satisfaction data was analyzed using McNemar's test, and local tolerability was assessed using the Bowker test.
Datasets
Not discussed in the paper. The study utilized data collected from participants during the clinical trial.
Key Insights and Ideas
- Direct Comparison is Key: The paired-design approach, where each participant received both treatments on opposite sides of their face, is a powerful way to control for individual variability in pain perception and response to anesthesia.
- Beyond Just Pain Relief: While pain reduction is primary, patient and investigator satisfaction are crucial for real-world adoption. The high satisfaction rates for both treatments underscore their clinical utility.
- Safety First: The study meticulously tracked adverse events, confirming that CU-30101 not only matches Pliaglis in efficacy but also in its favorable safety profile, with no severe adverse events reported.
- Addressing Market Gaps: The introduction of CU-30101 offers a much-needed alternative for effective topical anesthesia in the Chinese market, where options have been limited.
Key Results
- Equivalent Efficacy: The mean VAS scores were 35.3±24.51 for CU-30101 and 37.3±24.17 for Pliaglis. The 95% CI for the difference in VAS scores (-3.78 to -0.13) fell within the predefined equivalence margin of ±4.7, confirming equivalent efficacy (p=0.036). This equivalence was also supported by the per-protocol set analysis.
- High Satisfaction: Both participants and investigators reported consistently high satisfaction with both CU-30101 and Pliaglis regarding pain relief and the likelihood of future use.
- Favorable Safety and Tolerability: Both treatments were well-tolerated, with similar rates of mild and moderate local adverse events before fractional laser treatment. After laser treatment, adverse event rates were minimal for both drugs. No severe adverse events, serious adverse events, or AEs leading to withdrawal or death were reported.
Limitations and Future Work
- Post-Laser AE Attribution: The study acknowledges that adverse events occurring after fractional laser treatment were assessed in relation to the study drug without specific differentiation from procedure-related effects. This means it's difficult to definitively attribute all post-laser AEs solely to the anesthetic.
- Limited Follow-up: The safety follow-up period was limited to 3 days, mirroring the original Pliaglis trial. While deemed sufficient for short-term safety, longer follow-up periods or more detailed dermatological assessments could further characterize long-term safety.
- Laser Parameter Variability: While the study allowed for various fractional laser types and parameters, this flexibility, though enhancing real-world applicability, could introduce variability in pain perception. Future studies might benefit from specifying laser parameters or conducting subgroup analyses.
- Gender Imbalance: The study had a predominance of female participants. While the paired design minimizes inter-individual confounding, future research with a more balanced gender distribution is needed to confirm equivalence across both sexes.
Despite these limitations, the study provides a strong foundation for the broader clinical application of CU-30101 in various superficial dermatological procedures, not just fractional laser resurfacing.
Summary updated